File:Pharmaceuticals-13-00373-g002-550.jpg
Babu wata babbar saƙa.
Pharmaceuticals-13-00373-g002-550.jpg (pikisal 550 × 536, girman fayil: 96 KB, irin MIME: image/jpeg)
Taƙaici
| Bayani |
English: Immunotherapy phase III studies in the first line treatment of Non-Small Cell Lung Cancer (NSCLC), includes Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150. https://doi.org/10.3390/ph13110373 |
| Rana | |
| Masomi |
First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. https://doi.org/10.3390/ph13110373 |
| Marubucin |
First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373. |
First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373
Lasisi
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
- Za ka iya:
- a raba – dan kwafa, yadawa da aika aikin
- dan maimaita – dan daukar aikin
- A karkashin wannan sharuddan
- Jinginarwa – Dole ku bada jinjina da ta dace, samar da linki zuwa lasisin, da kuma bayyana ko kunyi sauyi. Zaku iya haka ta yadda ta dace, amma ba kowace hanya ba wanda zai nuna mai-lasisin yana goyon bayan ku ba ko goyon bayan amfanin da kuke yi ba.
- Yada ahaka – Idan kuka maimaita, sabuntawa, ko kari akan wannan, dole ku bayar da gudunmuwar ku karkashin iri daya ko lasisi data dace kamar na asali.
Tarihin fayil
Ku latsa rana/lokaci ku ga fayil yadda yake a wannan lokaci
| Rana/Lokaci | Wadar sufa | Kusurwowi | Ma'aikaci | Bahasi | |
|---|---|---|---|---|---|
| na yanzu | 03:44, 10 Disamba 2020 | | 550 × 536 (96 KB) | Sannecola | Uploaded a work by First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373. from First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. https://doi.org/10.3390/ph13110373 with UploadWizard |
Amfani da fayil
Wadannan shafi na amfani wannan fayil:
Amfanin fayil a ko'ina
Wadannan sauran wikis suna amfani da fayil din anan
- Amfani a kan en.wikipedia.org
